Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Acetylsalicylic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cerebral Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 03, 2025
Lead Product(s) : Cilostazol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Gyeongsang National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Cilostazol and Endothelial Progenitor Cell
Details : Cilostazol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Cilostazol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Gyeongsang National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rebamipide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
Details : Mucosta (Rebamipide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastritis.
Product Name : Mucosta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2019
Lead Product(s) : Rebamipide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rebamipide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers
Details : Rebamipide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2019
Lead Product(s) : Rebamipide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rebamipide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rebamipide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2019
Lead Product(s) : Rebamipide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolvaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolvaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2019
Lead Product(s) : Tolvaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Details : Aripiprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2018
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aripiprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2017
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilostazol
Therapeutic Area : Neurology
Study Phase : Phase IV
Recipient : Asan Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cilostazol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Ischemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2015
Lead Product(s) : Cilostazol
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Recipient : Asan Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolvaptan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolvaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2015
Lead Product(s) : Tolvaptan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
